{
  "_notice": {
    "type": "free_key_offer",
    "message": "Free and anonymous access is staying. If this endpoint is in your pipeline, a free key adds advance notice before any schema change or deprecation. POST /v1/keys {\"email\": \"you@firm.com\"} — nothing else required. Something broken or missing? hello@clearmarket.fyi reaches a human.",
    "docs": "https://clearmarket.fyi/for-data/",
    "policy": "This field is additive and its shape will not change."
  },
  "event_id": "CM-EVT-9N0VN6C5X5",
  "slug": "eli-lilly-licenses-peptrons-smartdepot-by-october-7",
  "question": "Will Eli Lilly license Peptron's SmartDepot by October 7?",
  "category": "financials",
  "event_type": "BINARY",
  "ladder_distribution": null,
  "tags": [
    "financials",
    "eli-lilly",
    "peptron",
    "pharma-licensing",
    "2026",
    "biotech-deal"
  ],
  "catalyst_types": [],
  "catalyst_dates": [],
  "editorial_notes": "This market tracks whether Eli Lilly will execute a binding commercial license for Peptron's SmartDepot sustained-release drug delivery platform by October 7, 2026. A single Polymarket binary prices the outcome as yes or no. Resolution requires public disclosure of a qualifying licensing, technology transfer, or equity arrangement. Polymarket's UMA Optimistic Oracle determines settlement based on that public disclosure standard.",
  "venues_covered": [
    "polymarket"
  ],
  "primary_market_id": "CM-MKT-LHVTP1B039",
  "current_primary_mark": {
    "last_price": 0.13,
    "implied_probability": 0.13
  },
  "created_at": "2026-08-04T20:03:51.865287+00:00",
  "updated_at": "2026-08-04T20:03:51.865287+00:00",
  "markets": [
    {
      "market_id": "CM-MKT-LHVTP1B039",
      "event_id": "CM-EVT-9N0VN6C5X5",
      "platform": "polymarket",
      "platform_market_id": "0x4dcc97d8ae807d14ca6a1b0648c331f9a23bfbec7310d6d7bd3b369cd25aa1ba",
      "question": "Eli Lilly licenses Peptron’s SmartDepot by October 7?",
      "description": "This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.\n\nOnly commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. \n\nCo-devel",
      "contract_type": "binary",
      "settlement_currency": "USDC",
      "underlying_reference": "UMA Optimistic Oracle resolves based on public disclosure of a binding commercial licensing, technology transfer, or equivalent agreement between Eli Lilly and Peptron for SmartDepot technology by October 7, 2026.",
      "close_at": "2026-10-07T00:00:00Z",
      "resolve_at": "2026-10-07T00:00:00Z",
      "status": "open",
      "resolution": {
        "rules_raw": "This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.\n\nOnly commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. \n\nCo-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.\n\nThe primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.",
        "arbitration_model": "uma_oracle",
        "proposer": "managed_whitelist",
        "source": null,
        "source_status": "no_committed_source",
        "source_citation": null,
        "sources": [
          {
            "name": "official information from Eli Lilly and Peptron",
            "url": null,
            "provenance": "clearmarket_editorial"
          },
          {
            "name": "a consensus of credible reporting",
            "url": null,
            "provenance": "clearmarket_editorial"
          }
        ],
        "source_of_record": null,
        "source_mechanism": null,
        "source_type": null,
        "source_quality": null,
        "source_commitment": "uncommitted",
        "source_commitment_subtype": "uncommitted_placeholder",
        "source_hedge_text": null
      },
      "rcg": {
        "grade": "C",
        "score": 56,
        "caps": [
          "commitment_uncommitted_placeholder"
        ],
        "applied_factors": 6
      },
      "last_price": 0.13,
      "implied_probability": 0.13,
      "volume_24h_usd": 7.692306,
      "volume_total_usd": 11145.421578999998,
      "settlement_style": "occurrence",
      "direction": "occurrence",
      "threshold": null,
      "question_id": "CMX-488F7FBE24",
      "also_on": null,
      "tags": [
        "eli lilly",
        "eli lilly peptron",
        "licensing",
        "peptron",
        "pharma",
        "smartdepot"
      ],
      "eligibility_screens": null
    }
  ],
  "resolution_log": [],
  "_provenance": {
    "source": "clearmarket.fyi",
    "ref": "CM-EVT-9N0VN6C5X5",
    "terms": "Attribution required. clearmarket.fyi"
  }
}